echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first anniversary of the company's founding board, a text read 25 biopharmaceutical enterprises "report card"

    The first anniversary of the company's founding board, a text read 25 biopharmaceutical enterprises "report card"

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A year ago, on June 13th, the board officially opened, and the registration system for the issuance of new shares was implemented in China's securities market.year, the company handed over a beautiful "report card", the number of listed companies from the first 25 into the "hundreds of contention" era;these bright achievements are one of the results of the "test field" of China's capital market reform.stand on the year-to-year node, biomedicine as the six major industries in the department of the second-largest sector, in this year's harvest how? According to the Shanghai Stock Exchange, as of June 15, the total number of companies reporting science and technology companies had reached 340, according to the Shanghai Stock Exchange.of these, 131 registered, 110 enterprises have been listed and traded, submitted to register 34, through the Shanghai Municipal Committee meeting 5, has been inquired 90, has accepted 48, one enterprise suspended consideration, 31 enterprises to terminate the audit.data source: Shanghai Stock Exchange from the fund-raising situation, as of June 15, the 110 enterprises listed on the stock market raised a total of 127.392 billion yuan, with a total market value of more than 1.72 trillion yuan. among the, Jinshan Office (688111) and Micro Micro (688012) are among the "100 billion market value clubs", with 44 companies with a market capitalization of more than 10 billion.from the geographical distribution, listed enterprises are mainly concentrated in the eastern coastal areas, including 20 registered in Jiangsu, Guangdong, Beijing have 19, Shanghai 16, Zhejiang 11.data source: Shanghai Stock Exchange focused on the field of biomedicine, as of June 15, the company has listed 25 biopharmaceutical enterprises, accounting for 22.73 percent of the total number of listed enterprises, with a total market value of 397.631 billion yuan. among the, the highest market value is Huaxi Bio (688363), with a market capitalisation of $62.4 billion, far more than other similar enterprises.Due to the impact of the outbreak at the beginning of the year, many pharmaceutical stocks share prices rose, and even many enterprises through the outbreak of market value doubled.of these 25 enterprises, the market value of more than 10 billion enterprises accounted for about 60%, including Bai Aotai (688177), Southern Micromedicine (688029), Tebao Bio (688278), micro-core biology (688321) and other 15.scientific research strength is an important index to judge the gold content of science and technology enterprises, and the research input of enterprises is also the focus of the industry.data show that in 2019, 110 companies will invest more than 13.3 billion yuan in research and development., the total research and development investment (excluding undisclosed enterprises) in the biopharmaceutical sector in 2019 was RMB2,077 million, or 15.62 percent.from the total investment in research and development as a proportion of revenue, micro-core biology, Seno Medical (688108), Berry Pharmaceuticals (688166) three enterprises invested in research and development, of which micro-core biological research and development investment accounted for 45.02 percent of revenue, the highest proportion.also has Pumen Technology (688389), cardio-pulmons medicine (688016), Xiangsheng Medical (688358) and other eight enterprises invested more than 10% in research and development. in addition, the opening of the board, but also attracted a number of Hong Kong stock companies or listed companies to spin off the listing. such as the recent Weigao, Liaoning Chengda, Changchun High-tech and other announced the spin-off of the subsidiary landing board, following Junshi, Kangsino, stone medicine recently also announced the consideration of science board listing, TianshiLi biological is by the Hong Kong stock to report the board. in the view of economist Song Qinghui, as a research and development-driven industry, the pharmaceutical and biological industry in line with the positioning properties of the board. compared with traditional pharmaceutical companies, the future layout of innovative pharmaceutical companies will be recognized by the market, the price valuation will be higher and higher. he believes that the continued focus on high-end medical equipment, innovative drugs and their industrial chain, vaccines and other investment opportunities brought about by the new pharmaceutical infrastructure in the post-epidemic era is expected to continue to be the key support of the country in the pharmaceutical industry industry direction. 31 enterprises sprint unsuccessful sprint technology board enterprises are growing, during which there are not a short period of enterprises have been poured cold water. Shanghai Stock Exchange data show that in the dynamics of the stock audit project, there are 31 enterprises impact co-productboard failure, including Hao Obo Bio, Anhan Technology, Seren Bio, Yuandong Bio, Besda, Noconda and so on. from a time point of view, Beijing Nokonda Pharmaceutical Technology Co., Ltd. on July 24, 2019 terminated the application for listing of the board, the first to terminate the listing of biopharmaceutical enterprises. subsequently, Besda and Yuandong Bio terminated their applications for listing on August 7, 2019 and August 29, 2019, respectively. a Shanghai investment banker believes that the intensive declaration of science and technology board, but also more difficult to avoid some low-quality projects to seize the beach, many companies "removal of materials" and with the regulatory communication conclusions related. to some extent, has become a non-standardized way for regulators to strictly control the quality of the company. Xu Xiaoheng, an expert in investment and financing , believes that the company's technology-based properties, core technology and so on attach great importance to the company's core technology. the true integrity of data is also an important condition for enterprises to pass the audit, which reflects that the supervision of the company's proposed listed companies is very strict, through strict audit to the good entrance. looking back on the year of the Board of Science, it was a fruitful one. Li Gang, deputy director of the General Office of the Securities And Futures Commission, recently summarized the operation of the company's first year of board opening, said: "The opening of the board for a year, the establishment of the science and technology board and the pilot registration system started well, the promotion is relatively smooth, the main institutional arrangements withstood the market test, overall in line with expectations, the response of all parties positive." " The next step, the CSRC will be in accordance with the principle of misalignment of development, moderate competition, co-ordinate the relationship between the development of science and innovation board and other sectors of the capital market reform, support the science and technology board as soon as possible to form a certain scale, establish a good brand and demonstration effect; .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.